U.S. Stock News

If you are trying to work out whether NextDecade's current share price still reflects its long term potential, the key question is how the stock stacks up against its underlying value. The share price closed at US$4.86 recently, after a 7.4% decline over the last week and a 11.3% decline over the last month, with the one year return at a 46.3% loss and the five year return at 78.7%. Recent news around NextDecade has focused on its role in US liquefied natural gas projects and its efforts to...

If you are wondering whether SLM's share price still reflects good value after its long run as a student lending name, you are not alone. The stock last closed at US$26.00, with returns of a 3.1% decline over 7 days, a 4.9% decline over 30 days, a 5.1% decline year to date, and a 7.4% decline over 1 year. The 3 year and 5 year returns sit at 65.1% and 120.9% respectively. Recent coverage has focused on how SLM fits into the broader student loan and consumer credit conversation, with...

Edgewise Therapeutics (EWTX) updated investors on its late stage pipeline, outlining 2026 milestones for muscular dystrophy and cardiovascular programs. These include key sevasemten trial readouts and a potential future New Drug Application submission. See our latest analysis for Edgewise Therapeutics. The update on 2026 clinical milestones comes as Edgewise Therapeutics trades at $28.73, with a 90 day share price return of 92.95% and a 3 year total shareholder return of 160.24%. This...

If you are wondering whether VeriSign's share price still reflects fair value or if expectations have run ahead of the fundamentals, you are in the right place. VeriSign shares most recently closed at US$248.12, with returns of 0.7% over the last 7 days, 1.7% over the last 30 days, 3.2% year to date and 18.9% over 1 year, while the 3 and 5 year returns sit at 16.1% and 27.7% respectively. These price moves sit against a backdrop of ongoing attention on domain infrastructure providers and the...

If you are wondering whether Paycom Software's current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. The stock closed at US$147.48, with returns of a 6.4% decline over 7 days, a 9.4% decline over 30 days, a 3.2% decline year to date and a 29.0% decline over 1 year, alongside a 53.0% decline over 3 years and a 61.6% decline over 5 years, which may have shifted how investors view its risk and potential reward. Recent...

If you are looking at Qorvo and wondering whether the current share price reflects fair value or an opportunity, you are not alone. The stock last closed at US$79.85, with returns of a 0.5% decline over 7 days, a 6.8% decline over 30 days, a 7.4% decline year to date and an 8.8% decline over 1 year, alongside longer term returns of a 26.1% decline over 3 years and a 54.4% decline over 5 years. Recent attention on Qorvo has centered on how these share price moves fit with its position in the...

Option Care Health (OPCH) has drawn fresh attention after expanding its share repurchase authorization to US$1b, completing earlier buybacks, and issuing full year 2026 net revenue guidance of US$5.8b to US$6.0b. See our latest analysis for Option Care Health. Those announcements come after a strong run in the share price, with a 30 day share price return of 10.09% and a 90 day share price return of 26.51%, while the 1 year total shareholder return of 21.45% and 5 year total shareholder...

Earlier this month, National Vision Holdings, Inc. reaffirmed its earnings guidance for the 53 weeks ended January 3, 2026, maintaining expected net revenue between US$1.97 billions and US$1.99 billions. This confirmation of the revenue outlook reinforces management’s confidence in the company’s operating trajectory and offers investors increased clarity on near-term expectations. Next, we’ll examine how National Vision’s decision to reaffirm full-year earnings guidance shapes the company’s...

Lindsay Corporation (NYSE:LNN) has appointed Brett R. Coburn as Chief Accounting Officer. The leadership change affects responsibility for the company’s accounting, financial reporting, and internal controls. Investors may watch this appointment for any impact on Lindsay’s governance and financial oversight. Lindsay, trading at $122.99, has seen mixed share performance in recent years, with a 1.5% year-to-date return and a 1-year return of an 8% decline. Over 3 and 5 years, returns of a...

As the United States market experiences a rebound following recent volatility, with major indices like the Dow Jones and S&P 500 showing significant gains after addressing geopolitical tensions, investors are keeping a close eye on high-growth sectors. In this dynamic environment, identifying tech stocks with strong fundamentals and innovative potential can be crucial for navigating the opportunities presented by such market fluctuations.

Amid recent volatility in the U.S. markets, with major indices like the Dow Jones and S&P 500 experiencing significant fluctuations due to geopolitical tensions and economic policy shifts, investors are keenly observing opportunities that may arise from these movements. In such an environment, identifying stocks that are potentially undervalued based on intrinsic value estimates can offer a strategic advantage, as they might provide growth potential when market conditions stabilize.

Major stock indexes saw a significant rebound recently, with the Dow Jones adding 450 points after President Trump ruled out the use of force in Greenland. Amidst this backdrop of market volatility and geopolitical tensions, investors are exploring opportunities beyond traditional stocks. Penny stocks, often representing smaller or newer companies, continue to attract attention for their potential value and growth prospects. In this article, we explore three penny stocks that showcase...

UFP Industries recently reported that unit sales have fallen over the past two years, with earnings per share dropping faster than revenue and returns on capital slipping, pointing to past profit pools becoming harder to sustain. This combination of weaker volumes, compressed earnings, and declining capital efficiency raises fresh questions about how durable the company’s profit engine may be. Next, we’ll examine how the ongoing slide in earnings per share shapes UFP Industries’ investment...

What triggered the latest interest in Dana (DAN)? Dana (DAN) is back on investors’ radar after the company issued 2025 sales guidance of US$7.30b to US$7.70b, alongside preliminary 2025 results that landed at the high end of its own expectations. See our latest analysis for Dana. That guidance and the focus on profitability and balance sheet repair arrive after a strong run in the stock, with a 90 day share price return of 38.54% and a 1 year total shareholder return of 104.87%. This comes...

Corvus Pharmaceuticals recently reported positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of oral soquelitinib in moderate to severe atopic dermatitis, and confirmed plans to start a Phase 2 study in the first quarter of 2026. The cohort 4 data are particularly interesting because they show clinical activity in patients who had previously failed systemic treatments, including dupilumab and JAK inhibitors, while maintaining a favorable safety profile...

Service Corporation International (SCI) has been in focus after its latest quarter showed 4.4% year on year revenue growth, topping analyst expectations by 1.5%, while recent positive Wall Street coverage has added another layer of investor attention. See our latest analysis for Service Corporation International. The share price, which closed at $82.35, has had a 5.3% 30 day share price return and a 6.7% year to date share price return. The 5 year total shareholder return of 66.1% points to...

Disc Medicine recently faced a two-week postponement of the U.S. FDA’s review of its rare disease candidate bitopertin, as regulators raised questions about efficacy endpoints, data integrity, and potential abuse risk. At the same time, the company appointed industry veteran Lisa Amaya Price as Chief Human Resources Officer, signaling an effort to strengthen its organizational backbone as it prepares for possible commercialization. Next, we’ll examine how the FDA’s temporary review delay for...

Reverse split reshapes Ozop Energy Solutions share structure Ozop Energy Solutions (OZSC) is carrying out a 1 for 5,000 reverse stock split effective January 21, 2026. This move sharply consolidates its share count and changes the trading price per share. This type of corporate action does not alter the company’s reported revenue of US$0.32 million or its loss of US$6.95 million, but it can influence liquidity, trading behavior, and how different investors view the stock. See our latest...

Some investors may be wondering whether Workday is starting to look interesting at its current price, or whether the shares still carry a premium that is hard to justify. After closing at US$182.99, the stock has seen a 16.3% decline over the last 30 days and a 27.0% decline over the last year. These moves may have changed how some investors think about its growth potential and risk. Recent coverage has focused on Workday's position in enterprise software and its ongoing push to win and...

Omega Healthcare Investors (NYSE:OHI) is showing a strong technical breakout pattern, pointing to renewed investor interest in the healthcare REIT space. The breakout aligns with a confirmed uptrend and a solid technical setup that traders may use as a rule-based entry signal. With shares last closing at $45.04, the move is drawing fresh attention from investors watching healthcare focused real estate names. For context, Omega Healthcare Investors has delivered a 28.1% return over the past...

If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively. Recent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as...

If you are wondering whether Origin Bancorp's current share price reflects solid value or hidden risk, it helps to start by lining up the recent performance with what you are actually paying for the business. The stock last closed at US$39.70, with returns of 1.1% over 7 days, 2.1% over 30 days, 5.5% year to date, 13.1% over 1 year, 8.7% over 3 years, and 47.1% over 5 years. This gives useful context before comparing the price to fundamentals. Recent coverage has focused on Origin Bancorp's...

If you are wondering whether Zoom Communications at around US$81 per share is still a quality name or already priced for perfection, its current valuation story is worth a closer look. The stock has recently seen a 2.2% decline over the past week, a 9.5% decline over the past month, a 2.4% decline year to date and a 3.5% gain over the past year, while its 3 year and 5 year returns stand at 17.1% and a 78.3% decline respectively. Recent news coverage has focused on how Zoom Communications...

If you are trying to figure out whether Bilibili is attractively priced today, the key question is whether the recent share price reflects its underlying fundamentals or leaves room for value. Bilibili last closed at US$30.27, with a 7 day return of 3.6% decline, a 30 day return of 22.2% and a 1 year return of 77.5%, which sits alongside a 3 year return of 18.1% and a 5 year return of 76.0% decline. These moves sit against ongoing investor focus on Chinese tech and media names, where risk...